Sunday Nov 24
Insulet Revenue Set to Surge
Insulet By Raymond James & Associates We are raising our rating on Insulet to Outperform from Market Perform.
Insulet Corporation to Present at Upcoming Investor Conferences
Management is scheduled to present an overview of the Company on Tuesday, December 3, 2013 at 3:30 p.m. ET.
Insulet Corp. Given New $45.00 Price Target at Canaccord Genuity
The firm currently has a "buy" rating on the stock. Canaccord Genuity's price objective indicates a potential upside of 23.52% from the stock's previous close.
Insulet Corp. PT Raised to $46.00
The firm currently has a "buy" rating on the stock. Jefferies Group's price objective would indicate a potential upside of 26.27% from the stock's previous close.
Insulet Corporation Reports Third Quarter 2013 Results
Insulet Corporation , the leader in tubeless insulin pump technology with its OmniPod Insulin Management System, today announced financial results for the three and nine months ended September 30, 2013.